Hematological and Biochemical parameters study of female albino rats treated with lamotrigine drug
Article Sidebar
Main Article Content
Abstract
The present study was aimed to investigate the possible effects of the anti-epileptic drug lamotrigine (LTG) on some haematological and biochemical parameters in adult female rats. Forty-eight female rats were divided into three groups (each group=16). Group one can be considered as a control group, group two and three administrated lamotrigine drugs orally at a dose of 3.57mg/kg body weight and 7.14mg/kg body weight for 7,14,21,28 day and all groups fed with standard rat feed. The results showed that there were significant (P≤0.05) changes in haematological parameters in group two and three when compared with the control group during all period except the mean level of corpuscular haemoglobin concentration (MCHC). The liver enzyme aspartate transaminase (AST) and alanine transaminase (ALT) and serum urea, creatinine with calcium, potassium, sodium and chloride ion showed significant alteration in the treated group, the relative organ weight showed significant changes in group two and three in comparison with control group during 7,14,21 and 28 days. Estradiol level in group three increased at 7, 14 and 21 day and decreased at 28 days of treatment when compared with group two and the control group. This study suggested that treatment of healthy female albino rats with therapeutic doses of lamotrigine drug for 28 days generally affect on included parameters in this study.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Biale, M.(2012). Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia, 53(7):26–33.
[2] Leppik, I.E. (1994). Antiepileptic drugs in development: prospects for the near future.
Epilepsia, 35 ( 4): 29-40.
[3] Leach, M.J.; Harden, C.M. and Millar, A.A. (1986). Pharmacological studies of lamotrigine, a novel potential antiepileptic drug, II: Neurochemical studies on the mechanisms of action. Epilepsia, 27 (5): 490-497.
[4]Pellock, J.M. (1997). Lamotrigine. Journal of Child Neurology, 12(1): S1-S1
[5] Cohen, A.F. et al. (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clinical Pharmacology & Therapeutic, 42(5): 535–541.
[6] EURAP Study Group. (2006). Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology, 66(3): 354–360.
[7] Garnett, W.R. (1997). Lamotrigine: pharmacokinetics. Journal of Child Neurology, 12(1): S10–15.
[8] Doig, M.V. and Clare, R.A. (1991). Use of thermospray liquid chromatography - mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. Journal of Chromatography, 554(1-2): 181–189.
[9] Pickrell, W.O. et al. (2014). Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure, 23(1):77–80.
[10] Abu-rish, E.Y.; Elhayek, Sh. Y.; Mohamed, Y.S.; Hamad, I. and Bustanji, Y. (2017). Evaluation of immunomodulatory effects of lamotrigine in BALB/c mice. Acta Pharmaceutica, 67(4): 543–555
[11] Al-taee, A.A. (2016). Histological and Biochemical Study of Female Albino Rats (Rattus rattus) Treated with Lamotrigine. International Journal of PharmTechResearch,9(9): 321-329.
[12] Perez-Lloret, S.L.; De Mena,O.F.; Pieczanski,P.; and Moncalvo. J.R. (2012). Bioequivalence of Lamotrigine 50-mg Tablets in Healthy Male Volunteers: A Randomized, Single-Dose,2-Period, 2-Sequence Crossover Study. Arzneimittelforschung, 62(10):470-476.
[13] Milosheska, D. et al. (2016). Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. British Journal of Clinical Pharmacology, 82(2):399-411
[14] Roste, L.S.et al.(2003). Gonadal morphology and sex hormones in male and female Wistar rats
after long-term lamotrigine treatment. Seizure,12(8): 621–627.
[15] Sidhu J, Job S, Singh S, and Philipson R.(2006). The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. British Journal of Clinical Pharmacology, 61(2):191–199.
[16] Shin, J.W.; Seol, I.C. and Son, C.G. (2010) Interpretation of Animal Dose and Human Equivalent Dose for Drug Development. The Journal of Korean Oriental Medicine.31(3): 1-7.
[17] Peter, A. and Kellie, B. (2012). SPSS statistics: a practical guide version 20. Cengage learning, Australia. [18] Landmark, C.J. (2008). Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs .22(1):27–47.
[19] Hamer, H.M, et al. (2012). Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany – a nationwide population-based study in children and adults. Journal of Neurology, 259(11):2376–2384.
[20] Hsieh, L.P, and Huang, C.Y.(2011). Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study. Epilepsy Research ,96(1-2):81–88.
[21] Biton, V. (2006). Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opinion Drug Metabolism Toxicology, 2(6): 1009 – 1018.
[22] Sinz, M. W, and Remmel, R. P.(1991). Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metabolism Disposition,19(1): 149 – 153.
[23] Adeneye, A. A.; Ajagbonna, O. P.; Adeleke, T. I. and Bello, S.O. (2006). Preliminary toxicity and phytochemical studies of the stem bark aqueous extract of Musanga cecropioides in rats. Journal of Ethnopharmacology, 105(3):374–379.
[24] Guyton, A. C. and Hall, J. E. (2000). Textbook of Medical Physiology. 10th edn., Philadelphia: Saunders: p 421
[25] Zuk, A.; Targosz-Korecka, M. and Szymonski, M. (2011). Effect of selected drugs used in asthma treatment on morphology and elastic properties of red blood cells.International .Journal of Nanomedicine. 6: 249–257.
[26] Betts, T. (1992). Clinical uses of lamotrigine. Seizure. 1(1):3-6
[27] Shams El Dine, S.M. (2014). Possible effects of lamotrigine on liver of Wistar rats exposed to chemoconvulsion and Chronic Restraint model. American Journal of Psychiatry and Neuroscience. 2(4): 50-55.
[28] Ziegler D. et al. (2009). Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine. 10(2): 393-400
[29] Day, A.; Mayne, P. and Mayne, P.D. (1994). Clinical Chemistry in Diagnosis and Treatment. 6th edn. London: Ahodder Arnold Publication:
[30] Johnston, D.E. (1999). Special considerations in interpreting liver function tests. American Family Physician . 59(8):2223-2230.
[31] Meldrum, B.S. (1994). Lamotrigine a novel approach. Seizure. 3 (SupplA): 41-45.
[32] Fayad, M., Choueiri, R. and Mikati, M. (2000). Potential hepatotoxicity of lamotrigine. Pediatric Neurology. 22(1): 49-52.
[33] Paul, T. Giboney, M.D. (2005). Mildly elevated liver transaminase levels in the Asymptomatic Patient. American Family Physician. 71(6):1105-1110.
[34] Ali, A. et al.(2003). Lamotrigine is not hepatoxic in mice. Indian Journal of Pharmacology. 35(4): 248-249.
[35] McAuley, J.W. and Anderson, G.D. (2002). Treatment of epilepsy in women of reproductive age, pharmacokinetic considerations. Clinical Pharma-cokinetic. 41(8):559–579.
[36] Sidhu, J; Job, S.; Singh, S. and Philipson, R. (2006). The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. British Journal of Clinical Pharmacology. 61(2): 191–199.
[37] Reimers, A. (2014) New antiepileptic drugs and women. Seizure 23(8): 585-591.
[38] Niespodziany I, Leclère N, Vandenplas C, Foerch P, and Wolff, C.(2013). Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation. Journal of Neuroscience Research. 91(3):436–443.
[39] Stefani, A.; Spadoni,F. and. Bernardi, G.(1997). Differential Inhibition by Riluzole, Lamotrigine, and Phenytoin of Sodium and Calcium Currents in Cortical Neurons: Implications for Neuroprotective Strategies. Experimental Neurology.147(1):115-122.
[40] Grunze, H.; von Wegerer, J.; Greene, R.W. and Walden, J. (1998). Modulation of Calcium and Potassium Currents by Lamotrigine. Neuropsychobiology. 38(3): 131–138.